Grigoris T Gerotziafas
Overview
Explore the profile of Grigoris T Gerotziafas including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
66
Citations
804
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papageorgiou L, Elalamy I, Vandreden P, Gerotziafas G
Clin Appl Thromb Hemost
. 2022 Jun;
28:10760296221097969.
PMID: 35733370
Thrombotic and hemorrhagic complications are related to a significant rate of morbidity and mortality in patients with myeloproliferative neoplasms (MPNs), they are therefore called "thrombohemorrhagic" syndromes. Several clinical factors, such...
2.
Souliotis K, Golna C, Nikolaidi S, Dreden P, Vatheia G, Gerotziafas G
TH Open
. 2022 May;
6(2):e89-e95.
PMID: 35498378
Cancer-associated thrombosis (CAT) is the second cause of mortality after cancer itself. CAT is underestimated as a health challenge among oncologists, whereas the levels of awareness among patients and the...
3.
Antic D, Lefkou E, Otasevic V, Banfic L, Dimakakos E, Olinic D, et al.
Clin Appl Thromb Hemost
. 2022 Feb;
28:1076029620939181.
PMID: 35187959
Venous thromboembolism (VTE) is a multifactorial disease that can possibly affect any part of venous circulation. The risk of VTE increases by about 2 fold in pregnant women and VTE...
4.
Kantarcioglu B, Iqbal O, Lewis J, Carter C, Singh M, Lievano F, et al.
Clin Appl Thromb Hemost
. 2022 Feb;
28:10760296211056648.
PMID: 35167393
The progress in the development of various vaccine platforms against SARS-CoV-2 have been rather remarkable owing to advancement in molecular and biologic sciences. Most of the current vaccines and those...
5.
Gerotziafas G, Catalano M, Theodorou Y, Van Dreden P, Marechal V, Spyropoulos A, et al.
Thromb Haemost
. 2021 Jun;
121(8):992-1007.
PMID: 34169495
Background: One year after the declaration of the coronavirus disease 2019 (COVID-19) pandemic by the World Health Organization (WHO) and despite the implementation of mandatory physical barriers and social distancing,...
6.
Kantarcioglu B, Iqbal O, Walenga J, Lewis B, Lewis J, Carter C, et al.
Clin Appl Thromb Hemost
. 2021 Jun;
27:10760296211021498.
PMID: 34060379
Today the coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has become a global health problem. After more than a year with the pandemic, although our...
7.
Elabbadi A, Turpin M, Gerotziafas G, Teulier M, Voiriot G, Fartoukh M
Infection
. 2021 Jan;
49(3):559-562.
PMID: 33393065
Severe 2019 novel coronavirus infectious disease (COVID-19) with pneumonia is associated with high rates of admission to the intensive care unit (ICU). Bacterial coinfection has been reported to be rare....
8.
Gerotziafas G, Zografos T, Pantos I, Lefkou E, Carlo A, Fareed J, et al.
Clin Appl Thromb Hemost
. 2020 Dec;
26:1076029620964590.
PMID: 33284037
In patients with stable coronary artery disease (CAD) blood hypercoagulability figures among factors leading to thrombosis. Tissue factor (TF) exposure at ruptured plaque initiates blood coagulation and hypercoagulability is responsible...
9.
Gerotziafas G, Sergentanis T, Voiriot G, Lassel L, Papageorgiou C, Elabbadi A, et al.
Thromb Haemost
. 2020 Sep;
120(12):1680-1690.
PMID: 32961572
The prospective observational cohort study COMPASS-COVID-19 aimed to develop a risk assessment model for early identification of hospitalized COVID-19 patients at risk for worsening disease. Patients with confirmed COVID-19 ( ...
10.
Gerotziafas G, Catalano M, Colgan M, Pecsvarady Z, Wautrecht J, Fazeli B, et al.
Thromb Haemost
. 2020 Sep;
120(12):1597-1628.
PMID: 32920811
COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or...